Lv11
70 积分 2025-01-04 加入
Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study
1小时前
已完结
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases
2天前
已完结
Immune Checkpoint Inhibitors in High-grade Gastroenteropancreatic Neuroendocrine Neoplasms
1个月前
已完结
Histopathologic and genetic distinction of well-differentiated grade 3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-grade neuroendocrine neoplasms
2个月前
已关闭
Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
2个月前
已完结
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study
2个月前
已完结
Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
2个月前
已完结
Paclitaxel‐carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series
2个月前
已完结
Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review
3个月前
已关闭
Therapeutic Options for Neuroendocrine Tumors
3个月前
已完结
皖公网安备34019202002308
